LONG-ACTING INJECTABLE BROMOCRIPTINE (PARLODEL LAR) IN THE CHRONIC TREATMENT OF PROLACTIN-SECRETING MACROADENOMAS
dc.contributor.author | Lengyel, Ana Maria Judith [UNIFESP] | |
dc.contributor.author | Mussio, Wania [UNIFESP] | |
dc.contributor.author | Imamura, Paulo Mitsuru [UNIFESP] | |
dc.contributor.author | Vieira, Jose Gilberto Henriques [UNIFESP] | |
dc.contributor.author | Lancranjan, Ioana | |
dc.contributor.institution | Universidade Federal de São Paulo (UNIFESP) | |
dc.contributor.institution | SANDOZ PHARMA LTD | |
dc.date.accessioned | 2018-06-15T17:30:17Z | |
dc.date.available | 2018-06-15T17:30:17Z | |
dc.date.issued | 1993-05-01 | |
dc.description.abstract | Objective: To evaluate the efficacy and tolerability of Parlodel LAR (Sandoz, Basel, Switzerland), a long-acting injectable bromocriptine, in PRL-secreting macroadenomas.Design: Eleven patients with macroprolactinomas were studied in an academic environment in an open and prospective protocol. Ten patients were followed for 6 months and 8 for 1 year. Fifty to 200 mg IM of Parlodel LAR were administered every 28 days.Results: At the end of the 1st month, 64% of the patients had PRL suppression of >75% of baseline values. After 1 year, 88% of the cases had PRL suppression of >90%. Persistent PRL normalization was seen in three cases. Tumor shrinkage was seen in 64% of the patients on day 5, in 73% on day 28, and in 90% after 6 months of treatment. Early visual field improvement was seen in 83% of the cases. All patients had improvement of clinical symptoms.Conclusion: Parlodel LAR is well tolerated and very effective in the long-term treatment of patients with PRL-secreting macroadenomas. | en |
dc.description.affiliation | ESCOLA PAULISTA MED SCH,DIV OPHTHALMOL,BR-04034 SAO PAULO,BRAZIL | |
dc.description.affiliation | SANDOZ PHARMA LTD,DEPT NEUROENDOCRINOL,BASEL,SWITZERLAND | |
dc.description.affiliationUnifesp | ESCOLA PAULISTA MED SCH,DIV OPHTHALMOL,BR-04034 SAO PAULO,BRAZIL | |
dc.description.source | Web of Science | |
dc.format.extent | 980-987 | |
dc.identifier | http://www.fertstert.org/article/S0015-0282(16)55914-7/pdf | |
dc.identifier.citation | Fertility And Sterility. Birmingham: Amer Soc Reproductive Medicine, v. 59, n. 5, p. 980-987, 1993. | |
dc.identifier.doi | 10.1016/S0015-0282(16)55914-7 | |
dc.identifier.issn | 0015-0282 | |
dc.identifier.uri | http://repositorio.unifesp.br/handle/11600/43681 | |
dc.identifier.wos | WOS:A1993LB26900007 | |
dc.language.iso | eng | |
dc.publisher | Amer Soc Reproductive Medicine | |
dc.relation.ispartof | Fertility And Sterility | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | PARLODEL LAR | en |
dc.subject | MACROPROLACTINOMAS | en |
dc.subject | INJECTABLE BROMOCRIPTINE | en |
dc.subject | PRL-SECRETING MACROADENOMAS | en |
dc.subject | CHRONIC TREATMENT | en |
dc.title | LONG-ACTING INJECTABLE BROMOCRIPTINE (PARLODEL LAR) IN THE CHRONIC TREATMENT OF PROLACTIN-SECRETING MACROADENOMAS | en |
dc.type | info:eu-repo/semantics/article |